avapro has been researched along with Cirrhosis, Liver in 7 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Additionally, they randomly received either placebo (N = 15) or irbesartan (step-up dosage titration up to 300 mg/d, N = 17)." | 2.73 | Irbesartan plus low-dose propranolol versus low-dose propranolol alone in cirrhosis: a placebo-controlled, double-blind study. ( Flacke, S; Ghauri, M; Heller, J; Herold, T; Sauerbruch, T; Schepke, M; Stoffel-Wagner, B; Wiest, R, 2008) |
| "The effect of hepatic impairment on the clinical pharmacology of the angiotensin II (AII) receptor antagonist irbesartan was assessed by comparing pharmacokinetic and pharmacodynamic parameters in 10 patients with hepatic cirrhosis with a matched group of 10 healthy volunteers." | 2.69 | Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis. ( Ford, NF; Langenbacher, KM; Lasseter, KC; Marino, MR; Raymond, RH, 1998) |
| "Non-alcoholic steatohepatitis (NASH) is the hepatic manifestation of a metabolic syndrome characterized by accumulation of hepatic fat, inflammation and varying degrees of fibrosis." | 1.38 | Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice. ( Kato, J; Kishina, M; Koda, M; Matono, T; Murawaki, Y; Sugihara, T; Tokunaga, S; Ueki, M, 2012) |
| "Non-alcoholic steatohepatitis (NASH), which is a common liver disease in industrialized countries, is associated with obesity, hypertension, and type-2 diabetes (metabolic syndrome)." | 1.35 | ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. ( Cao, G; Mastai, R; Mella, J; Muñoz, MC; Pereyra, L; Toblli, JE, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kato, J | 1 |
| Koda, M | 1 |
| Kishina, M | 1 |
| Tokunaga, S | 1 |
| Matono, T | 1 |
| Sugihara, T | 1 |
| Ueki, M | 1 |
| Murawaki, Y | 1 |
| Venon, WD | 1 |
| Baronio, M | 2 |
| Leone, N | 1 |
| Rolfo, E | 1 |
| Fadda, M | 1 |
| Barletti, C | 2 |
| Todros, L | 2 |
| Saracco, G | 2 |
| Rizzetto, M | 2 |
| Toblli, JE | 1 |
| Muñoz, MC | 1 |
| Cao, G | 1 |
| Mella, J | 1 |
| Pereyra, L | 1 |
| Mastai, R | 1 |
| Schepke, M | 2 |
| Wiest, R | 1 |
| Flacke, S | 1 |
| Heller, J | 2 |
| Stoffel-Wagner, B | 2 |
| Herold, T | 1 |
| Ghauri, M | 1 |
| Sauerbruch, T | 2 |
| Marino, MR | 1 |
| Langenbacher, KM | 1 |
| Raymond, RH | 1 |
| Ford, NF | 1 |
| Lasseter, KC | 1 |
| Werner, E | 1 |
| Biecker, E | 1 |
| Schiedermaier, P | 1 |
| Neef, M | 1 |
| Hofer, U | 1 |
| Caselmann, WH | 1 |
| Debernardi-Venon, W | 1 |
| Alessandria, C | 1 |
| Marzano, A | 1 |
| Repici, A | 1 |
4 trials available for avapro and Cirrhosis, Liver
| Article | Year |
|---|---|
Effects of long-term Irbesartan in reducing portal pressure in cirrhotic patients: comparison with propranolol in a randomised controlled study.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pr | 2003 |
Irbesartan plus low-dose propranolol versus low-dose propranolol alone in cirrhosis: a placebo-controlled, double-blind study.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphe | 2008 |
Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Bip | 1998 |
Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Bilirubin; Biphenyl Compounds; Double-Bli | 2001 |
3 other studies available for avapro and Cirrhosis, Liver
| Article | Year |
|---|---|
Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Comp | 2012 |
ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats.
Topics: Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme I | 2008 |
Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Female; Hemodynamics; | 2002 |